Board of Directors
Sanjay D. Khare, PhD
President and CEO, Chairman of the Board
Dr. Khare founded ImmunGene in 2008, where he has been serving as a President and CEO. Previously, Dr. Khare spent almost 9 years at Amgen Inc with increasing responsibility to Scientific Director in the department of Inflammation/Immunology. While at Amgen, Dr. Khare co-discovered key immune co-stimulatory molecules such as B7RP1 and B cell activating Factor (e.g. BAFF). Dr. Khare led several drug discovery programs related to immune cell costimulation and bifunctional molecules to optimize therapeutics. Dr. Khare is co-inventor of several patents while working in Amgen and as an advisor to the start up Biotech companies. Several of these inventions have resulted in more than US$1B potential deals from large Pharmaceutical companies. Dr. Khare coauthored more than 50 scientific papers, abstracts and edited a book on TNF superfamily. Dr. Khare has successfully capitalized ImmunGene from Angel investors, VC fundings, non-profit organization (LLS) and the NIH-SBIR. Sanjay received his Ph.D. in Immunology at the All-India Institute of Medical Sciences, New Delhi, India and did his postdoctoral fellowship in the Immunology department at the Mayo Clinic and Medical School. He is a recipient of ASHI scholar award in 1997.
Michael J. Gresser, PhD
Chief Scientific Officer, ImmunGene Board Member and SAB Member
Dr. Gresser received his Ph.D in Biochemistry in 1976 from Brandeis University. He did postdoctoral studies at the Molecular Biology Institute at UCLA under the supervision of Paul D. Boyer. In 1980 Mike joined the Department of Chemistry at Simon Fraser University in Burnaby, British Columbia, and progressed to Professor of Chemistry. While there Mike received the Excellence in Teaching Award, and did research on the biochemistry of Vanadium V, and on the mitochondrial ATPase. In 1988 Mike Joined the Merck Frosst Center for Therapeutic Research in Kirkland, Quebec as Director of Biochemistry. Over the next twelve years Mike progressed through the ranks of Senior Director, then Executive Director of Biochemistry and Molecular Biology. Mike's team worked on a variety of small molecule drug discovery programs, resulting in the introduction of numerous molecules into clinical trials. Two of these molecules, Singulair and Vioxx, became products. In 2000 Mike joined Amgen Inc. in Thousand Oaks, California, as Vice President of Research for Inflammation, where he remained until April, 2006. For two years Mike served as Head of Neuroscience Research as well as Inflammation Research. Mike's team at Amgen worked on taking many molecular targets, introducing numerous small molecules, human antibodies and other proteins into development. Currently Mike is a Visiting Scholar at the Molecular Biology Institute at UCLA, and works as a consultant with Clarity Therapeutics Consulting.
ImmunGene Board Member
Mr. Yu is Founder and CEO of Ally Bridge Group, a global healthcare-focused investment platform with bases in Hong Kong and the United States, and Co-Founder and CEO of Themes Investment Partners, a China-focused private equity fund. Mr. Yu has led and actively manages Themes’ and Ally Bridge’s investments in medtech companies including Lifetech Scientific (Medtronic’s strategic partner in China), LoneStar Heart, Sonendo, Metronom Health and Broncus Medical;and biopharmaceutical companies including China Animal Health (Eli Lilly-Elanco’s strategic partner in China), Apexigen, Kato Pharmaceutical and ImmunGene. Mr. Yu has expertise in cementing strategic transactions between emerging players and industry leaders, between global companies and leading players in China, and helping global companies access the China market.
Previously, Mr. Yu was Managing Director and Head of China Investments at Och-Ziff Capital Management, a leading global hedge fund. Prior to Och-Ziff, Mr. Yu was a Managing Director at Goldman Sachs Hong Kong, where he played instrumental roles in some of the most important restructuring, initial public offering (IPO) and merger and acquisition (M&A) transactions of leading Chinese companies, and advised leading global institutions on their China and Asia strategies and transactions. Before Goldman Sachs, Mr. Yu worked at Moody’s in New York, and then Credit Suisse in London and Hong Kong.
Raj Sachdev, PhD
Chief Operating Officer, ImmunGene Board Member
Dr. Sachdev received his PhD, in Chemical Engineering from Biochemical Engineering Research Center, Indian Institute of Technology, New Delhi in 1979. After post doctoral work at various institutions: Technical University of Denmark, National Institute of Health, Maryland, and Drexel University, Philadelphia, Raj joined Amgen Inc. as a Process Development Research Scientist in Dec. 1984. He gained extensive experience in Microbial Fermentation/Mammalian Cell Culture Process Development, Scale up, Yield Improvement, Optimization, Technology Transfer and Manufacturing Technical Support at Amgen with increasing responsibilities. Raj joined Baxter Bioscience in 1999 as Manager of the Technical Operations Group that provided manufacturing support for Factor-VIII production, including Cell culture, Purification, and Formulation and Lyophilization unit operations. He moved to Shire HGT in Cambridge MA, and joined as Senior Director of Manufacturing Technical Support. Raj has two process patents and is coauthor of several publications/presentations.